Skip to content

The Longitudinal approach to Acromegaly in China: a pattern of Treatment and Comparative Effectiveness Research

The Longitudinal approach to Acromegaly in China: a pattern of Treatment and Comparative Effectiveness Research

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17013525
Enrollment
Unknown
Registered
2017-11-24
Start date
2017-11-30
Completion date
Unknown
Last updated
2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Interventions

Surgery Group:Surgery such as Transnasal butterfly surgery
Drug Group:Drug treatment includes somatostatin analogues (SSA), dopamine receptor agonists and GH receptor antagonists
Radiotherapy Group:Conventional radiotherapy methods include radiotherapy, linear accelerator X knife, gamma knife

Sponsors

Huiwen Tan, Zhiyong Chen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The patient population that will be observed in the study must fulfill all of the following criteria: 1. Be able and willing to sign the informed consent form (ICF); 2. Male, female, aged 18-75 years old (including 18 years old and 75 years old); 3. Compliance with acromegaly diagnostic criteria: (1) At least one laboratory or medical record shows that the patient is random GH = 2.5 ug/L; (2) At least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor.

Exclusion criteria

Exclusion criteria: Patients meeting any of following exclusion criteria will not be eligible: 1. Ectopic secretion of GH or pituitary cancer; 2. The patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue; 3. Have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study; 4. Those patient who, in the judgement of the Investigator, to be inappropriate for enrollment in this study.

Design outcomes

Primary

MeasureTime frame
Cause of death;

Secondary

MeasureTime frame
GH;IGF-1;Acromegaly symptoms;Questionnaire (ACROQoL?EQ-5D-3L);Radiographic image;

Contacts

Public ContactShengrong Xie

Nanjing Yuhua GinkgoLeaf Rare Disease Family Care Centre

xieshengrong81@126.com+86 18662702387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026